Palliative radiotherapy is an effective means of alleviating pain and improving overall quality of life in elderly patients with bone metastases, according to a new study.

A large study shows that middle-age men engaged in lots of cardiovascular exercise have a reduced risk of developing and dying from lung and colorectal cancer.

Findings suggesting that obesity substantially impairs the ability of L-asparaginase to kill leukemia cells were reported last month by investigators from The Saban Research Institute, Children’s Hospital Los Angeles.

The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in average-risk men based upon evidence from a systematic literature review. The guideline, which was announced during the 2013 AUA Annual Meeting, recommends that men aged 55 to 69 years who are considering undergoing prostate cancer screening should talk with their physicians about the benefits and risks of screening.

Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic variations could help clinicians single out higher-risk men for screening and early detection.

The FDA approved a label expansion for erlotinib (Tarceva), along with the cobas EGFR mutation diagnostic test, to include patients untreated metastatic NSCLC patients whose tumors have either a deletion in exon 19 or exon 21 (L858R) substitution mutations in the EGFR gene.

Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has metastasized to the bone but no other organs.

The use of statins was independently associated with improvements in overall survival and disease-specific survival among a group of patients who had undergone partial or radical nephrectomy for renal cell carcinoma.

A cohort-based study found that men with prostate cancer who took cholesterol-lowering statins had a lower risk of dying from their prostate cancer.

Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients.

Expression of the beta-3 tubulin (ß3T) isoform was a negative prognostic factor in non–small-cell lung cancer (NSCLC) patients, but did not predict treatment response for either paclitaxel or tubulin-inhibiting chemotherapy with ixabepilone.

A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association.

In the HERA trial, benefit for invasive lobular breast cancer patients with 1 year of trastuzumab maintenance was similar to invasive ductal carcinoma patients.

Adding the VEGF inhibitor axitinib to first-line treatment of FOLFOX-6 for metastatic colorectal cancer failed to improve progression-free and overall survival.

A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab.

Researchers have characterized acute myeloid leukemia, providing new genetic driver leads to help classify the disease and even stratify AML patients by risk.

The FDA’s Oncologic Drugs Advisory Committee has voted 13 to 1 against AVEO's drug tivozanib for the treatment of patients with metastatic renal cell carcinoma.

A group of experts say that cancer drug prices, especially those for chronic myeloid leukemia, have skyrocketed, making patient treatment extremely difficult.

A majority of patients with multiple myeloma are being treated with novel agents such as thalidomide, bortezomib, and lenalidomide within a year of diagnosis instead of the chemotherapeutic regimens that were more prevalent a decade ago, according to a new study.

Multiple myeloma patients are at increased risk of developing myelodysplastic syndrome or acute leukemia after maintenance lenalidomide or thalidomide treatment, according to a new study.

A new study shows that drugs targeting HER2 might provide good results in the rare non-small-cell lung cancer (NSCLC) patients with HER2 mutations.

Four of the nation’s cancer organizations--including the COA and ASCO--believe that the sequestration cuts will impact the treatment of cancer patients on Medicare and have sent letters to Congress and the Department of Health and Human Services.

Oncologists hit by sequester budget cuts to the cost of purchasing and administering cancer drugs are hoping that the potentially devastating impact on Medicare cancer patients will force a quick legislative fix in Congress.

A case-control study of almost 500 men suggests that obese men who have had a benign prostate biopsy have a greater risk of prostate cancer in the future.

New guidelines make recommendations on how physicians should conduct themselves online, examining the effect of Facebook and Twitter on patient-physician relationships.